Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | BCL9 | O00512 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.36 |
| ▸ | PTPN12 | Q05209 | 1/20 | 0.36 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924446 | 0.82 | RAB9A (0.46) | GAAKMT2APKMALDH1A1SMN1; SMN2 | |
| SCHEMBL15168 | 0.82 | GAA (0.61) | GAABCL9CTNNB1KMT2APKM | |
| Ammonia Solution, Strong SCHEMBL19516242 | 0.80 | GAA (0.59) | GAABCL9CTNNB1KMT2APKM | |
| Benzene SCHEMBL28222061 | 0.79 | GAA (0.57) | GAABCL9CTNNB1KMT2APKM | |
| SCHEMBL9276769 | 0.79 | GAA (0.57) | GAABCL9CTNNB1KMT2APKM | |
| Bicarbonate SCHEMBL600121 | 0.79 | GAA (0.57) | GAABCL9CTNNB1KMT2APKM | |
| SCHEMBL25236596 | 0.77 | GAA (0.56) | GAABCL9CTNNB1KMT2APKM | |
| Ethylene Glycol SCHEMBL23277093 | 0.76 | BCL9 (0.55) | GAABCL9CTNNB1KMT2APKM | |
| P-Nitrophenol SCHEMBL1960699 | 0.76 | GAA (0.54) | GAABCL9CTNNB1KMT2APKM | |
| SCHEMBL6564201 | 0.75 | ELANE (0.52) | KMT2AALDH1A1SMN1; SMN2RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321042-A1 | COMBINATION THERAPY | PFIZER INC. (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230055741-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | Ryvu Therapeutics S.A. (PL) | 2023-02-23 | — | — | US | disclosed |
| WO-2022094012-A1 | MACROCYCLIC UREA OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2022-05-05 | — | — | WO | disclosed |
| WO-2013037415-A1 | SUBSTITUTED 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDINES, THEIR USE AS MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM | SANOFI (FR) | 2013-03-21 | — | — | WO | disclosed |
| US-20070149553-A1 | Mitotic kinesin inhibitors | ARRINGTON KENNETH L | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149553-A1 | Mitotic kinesin inhibitors | KIF5B, KIF2C, KIF18B | GAA 1263/4885BCL9 2952/4885CTNNB1 3522/4885 |
| US-20230321042-A1 | COMBINATION THERAPY | CDK4, CDK6, CDK2 | GAA 3572/4885BCL9 270/4885CTNNB1 901/4885 |
| US-20230055741-A1 | FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) | STING1, IRF3, CGAS | GAA 201/4885BCL9 1635/4885CTNNB1 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.